Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-08-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于2021年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a public offering. It includes specifics on the amount raised, the timing, the use of funds during the reporting period, the balance remaining, and compliance with regulatory requirements. The document references the Chinese Securities Regulatory Commission approval and includes detailed tables on fund usage, investment projects, and cash management. This type of document is a specialized report on the use of raised capital, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim financial report, nor is it an announcement of a report publication. The length and detail confirm it is a substantive report rather than a brief announcement or certification. Therefore, the correct classification is CAP with high confidence.
2021-08-29 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司预计2021年度日常性关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the expected 2021 annual related party transactions of a listed company. It includes transaction amounts, related party information, compliance with regulations, and opinions from independent directors and the board. The content focuses on the review and approval of related party transactions, which is a form of audit or regulatory compliance report rather than a full annual or quarterly financial report. It is not a simple announcement or a brief summary but a formal audit-related opinion document. Therefore, it fits best under the category of Audit Report / Information (AR).
2021-08-29 Chinese
圣湘生物科技股份有限公司第一届监事会2021年第五次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 圣湘生物科技股份有限公司 regarding the approval of the company's 2021 half-year report and a special report on the use of raised funds. It confirms the completion and verification of the half-year report but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (808 characters) and serves as an official announcement of the Supervisory Board's meeting decisions rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2021-08-29 Chinese
圣湘生物科技股份有限公司2021年半年度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度报告" which translates to "2021 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, environmental and social responsibility, shareholder information, and a full set of financial statements. The report covers the period from January 1, 2021 to June 30, 2021, indicating it is a comprehensive interim financial report for half a year. The document length is about 15,000 characters, which is consistent with a full interim report rather than a brief announcement or summary. The presence of detailed financial metrics, management analysis, and extensive company information confirms this is an Interim / Quarterly Report (IR). H1 2021
2021-08-29 Chinese
圣湘生物科技股份有限公司2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The length is 3205 characters, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data. It is not merely an announcement or a certification, but a report summary with financial figures and shareholder data. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2021
2021-08-29 Chinese
圣湘生物科技股份有限公司2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2021 second extraordinary general meeting of shareholders. It includes details about the meeting date, attendance, voting results, and legal validation by lawyers. There is no financial data or report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2021-08-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.